15gag proteinase of myeloblastosis-associated virus: specificity studies with substrate-based inhibitors
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu srovnávací studie, časopisecké články
PubMed
1417001
DOI
10.1016/0003-9861(92)90476-d
PII: 0003-9861(92)90476-D
Knihovny.cz E-zdroje
- MeSH
- aspartátové endopeptidasy antagonisté a inhibitory MeSH
- HIV-1 enzymologie MeSH
- HIV-proteasa metabolismus MeSH
- inhibitory proteas chemická syntéza farmakologie MeSH
- kinetika MeSH
- molekulární sekvence - údaje MeSH
- oligopeptidy chemická syntéza farmakologie MeSH
- sekvence aminokyselin MeSH
- substrátová specifita MeSH
- virus ptačí myeloblastózy enzymologie MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Názvy látek
- aspartátové endopeptidasy MeSH
- HIV-proteasa MeSH
- inhibitory proteas MeSH
- oligopeptidy MeSH
- protease p15 MeSH Prohlížeč
The specificity of the proteinase of myeloblastosis-associated virus (MAV) was studied with (a) 21 substrate-based inhibitors, (b) 9 inhibitors with pseudopalindrome sequences, (c) 8 chimeric inhibitors, and (d) 3 compounds designed as human immunodeficiency virus 1 (HIV-1) proteinase inhibitors. The central inhibitory unit (transition state or cleaved bond analog) and the role of the inhibitor side chains from P4 to P4' were investigated. MAV proteinase prefers an aromatic side chain in P1 and a small aliphatic nonpolar chain in P2 and P2'. Residues in P5 and P4 positions are outside of the short catalytic cleft of the enzyme, but still influence binding considerably. The data obtained provide evidence that the MAV proteinase has generally lower specificity and poorer binding than the HIV proteinase.
Citace poskytuje Crossref.org